CHAPTERS
Can aging be slowed—or reversed? Setting the stakes for longevity science
Joe opens by asking whether anti-aging is realistic, and Sinclair answers that slowing, stopping, and even reversing aspects of aging are all plausible based on lab work. The conversation quickly shifts to what’s already working in animals and what it would take to translate that to humans.
Sinclair’s personal longevity routine: fasting, supplements, and lifestyle stressors
Sinclair details what he actually does day-to-day: intermittent fasting, weight control, specific supplements, and deliberate exposure to mild stress (sauna/cold). Rogan probes for practical specifics and whether the regimen is additive with exercise and diet.
Resveratrol, NMN/NR, NAD: the ‘fuel and accelerator’ model for sirtuins
Sinclair explains the core biochemical story behind his supplement choices: sirtuin genes, their dependence on NAD, and how NMN/NR raise NAD levels. He describes resveratrol as an activator and NMN as the fuel, emphasizing age-related NAD decline.
Metformin, AMPK, mTOR: three major longevity pathways—and why rapamycin is risky
Rogan asks why Sinclair takes metformin without diabetes, prompting a map of aging-regulating pathways. Sinclair outlines AMPK, sirtuins, and mTOR, positioning drugs/diet as ways to tune these systems while warning against casual rapamycin use.
Protein, red meat, and performance trade-offs: mTOR, BCAAs, and ‘disposable soma’
The discussion turns to diet composition—especially protein and red meat—and how short-term performance can conflict with long-term longevity. Sinclair explains why BCAAs and high amino acid loads may boost performance yet shorten lifespan in animal studies, tying it to evolutionary trade-offs.
Why ‘antioxidants’ aren’t the answer: hormesis and plant polyphenols
Sinclair challenges popular aging narratives (free radicals/antioxidants) and reframes benefits as stress-response activation. He explains hormesis and why stressed plants produce polyphenols like resveratrol that can trigger protective pathways in animals.
Young blood, startups, and treating aging as a disease—plus the overpopulation debate
Rogan asks about young-blood transfusion startups; Sinclair says the premise is plausible but prefers isolating the active factors. They then debate whether aging should be classified as a disease and address societal implications like healthcare costs and population growth.
Blue Zones and calorie restriction: Okinawa, portion control, and fasting practicality
Sinclair and Rogan discuss populations associated with longevity (Blue Zones), focusing on Okinawa’s lifestyle. They compare strict calorie restriction (powerful but hard) with intermittent fasting as a more sustainable approach that may deliver similar benefits in animals.
The epigenome theory of aging: ‘scratched DVD’ information loss and DNA breaks
Sinclair presents his central model: aging is driven less by DNA mutations and more by epigenetic ‘information’ degradation—how cells read genes. He uses the scratched CD/DVD analogy to explain how DNA breaks and repair can disrupt the epigenome over time.
Cellular reprogramming and restored vision in mice: glaucoma trial roadmap
Sinclair describes partial reprogramming via key genes delivered by viral vectors, including dramatic mouse results in optic nerve injury, glaucoma models, and aged vision decline. They discuss safety concerns (e.g., tumor risk) and plans for initial human safety studies targeting glaucoma.
Measuring biological age: blood tracking, InsideTracker, and the DNA methylation clock
They pivot to monitoring: how to know what’s working, how often to test, and why annual physicals are inadequate. Sinclair introduces biomarker tracking and epigenetic clocks (Horvath-style methylation measures) as ways to quantify biological aging and possibly reversal.
Training, hormesis, and trade-offs: exercise dose, joints, and lifestyle realism
Rogan pushes on optimal exercise intensity and overtraining; Sinclair reiterates hormesis—enough stress to trigger repair, not so much to cause damage. They cover practical training structure, low-impact high-intensity work, and the value of maintaining muscle mass with age.
CRISPR and designer babies: ethics, secrecy, and international competition
Sinclair explains CRISPR as repurposed bacterial DNA-cutting immunity, then discusses the controversial case of edited twins in China. They explore why secrecy triggered backlash, the danger of off-target effects, and the reality that some efforts may be happening outside transparent oversight.
Biosecurity and pathogen detection: anthrax, biofilms, and rapid ‘unknown bug’ ID
Sinclair describes government-adjacent bio-defense work: safer ways to neutralize threats like anthrax, and diagnostics that identify all microbes in a sample quickly—even when you don’t know what you’re looking for. He ties it to real-world failures in infectious disease response and the need for modernized microbiology.
Science, money, and conflict-of-interest: building ethical longevity companies
They close on the realities of commercializing longevity: Sinclair’s startups, regulatory pathways, costs of trials, and pricing ethics. Sinclair emphasizes disclosure, avoiding endorsements, and creating a more trusted 21st-century pharma model while continuing foundational research.
